Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour

Annals of Oncology

Volumn 20, Issue 9, 2009, Pages 1582-1588

  Rikhof, B ^a   van Doorn, J ^b   Suurmeijer, A J H ^a   Rautenberg, M W ^c   Groenen, P J T A ^d   Verdijk, M A J ^d   Jager, P L ^e   de Jong, S ^a   Gietema, J A ^a   van der Graaf, W T A ^d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Gastrointestinal stromal tumour; IGF II; IGFBP 2; Imatinib; Non islet cell tumour induced hypoglycaemia

Indexed keywords

IMATINIB; PRO INSULIN LIKE GROWTH FACTOR IIE[68-88]; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SUNITINIB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYST FLUID; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SURVEILLANCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HISTOLOGY; HUMAN; HYPOGLYCEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; METASTASIS; NON ISLET CELL TUMOR INDUCED HYPOGLYCEMIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CYST FLUID; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; HYPOGLYCEMIA; INCIDENCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MALE; MIDDLE AGED; SOMATOMEDINS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 69849086161     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp038     Document Type: Article

References (35)

1. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 3813-3825.
2. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004; 364: 1127-1134.
3. De Groot JW, Rikhof B, Van Doorn J et al. Non-islet cell tumour-induced hypoglycaemia: A review of the literature including two new cases. Endocr Relat Cancer 2007; 14: 979-993.
4. Frystyk J, Skjaerbaek C, Zapf J, Orskov H. Increased levels of circulating free insulin-like growth factors in patients with non-islet cell tumour hypoglycaemia. Diabetologia 1998; 41: 589-594.
5. Beckers MM, Slee PH, Van Doorn J. Hypoglycaemia in a patient with a gastrointestinal stromal tumour. Clin Endocrinol (Oxf) 2003; 59: 402-404.
6. Rikhof B, Van den Berg G, Van der Graaf WT. Non-islet cell tumour hypoglycaemia in a patient with a gastrointestinal stromal tumour. Acta Oncol 2005; 44: 764-766.
7. Pink D, Schoeler D, Lindner T et al. Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: A report of two cases. J Clin Oncol 2005; 23: 6809-6811.
8. Hamberg P, De Jong FA, Boonstra JG et al. Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. J Clin Oncol 2006; 24: E30-e31.
9. Escobar GA, Robinson WA, Nydam TL et al. Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: A case report. BMC Cancer 2007; 7: 13.
10. Davda R, Seddon BM. Mechanisms and management of non-islet cell tumour hypoglycaemia in gastrointestinal stromal tumour: Case report and a review of published studies. Clin Oncol (R Coll Radiol) 2007; 19: 265-268.
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
12. Stroobants S, Goeminne J, Seegers M et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39: 2012-2020.
13. Blay JY, Bonvalot S, Casali P et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16: 566-578.
14. Jager PL, Gietema JA, Van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: Best monitored with FDG PET. Nucl Med Commun 2004; 25: 433-438.
15. Rikken B, Van Doorn J, Ringeling A et al. Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency. Horm Res 1998; 50: 166-176.
16. Van Doorn J, Hoogerbrugge CM, Koster JG et al. Antibodies directed against the E region of pro-insulin-like growth factor-II used to evaluate non-islet cell tumorinduced hypoglycemia. Clin Chem 2002; 48: 1739-1750.
17. De Boer L, Hoogerbrugge CM, Van Doorn J et al. Plasma insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), acid-labile subunit (ALS) and IGFBP-3 proteolysis in individuals with clinical characteristics of Sotos syndrome. J Pediatr Endocrinol Metab 2004; 17: 615-627.
18. Westra JL, Hollema H, Schaapveld M et al. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann Oncol 2005; 16: 1646-1653.
19. Van Doorn J, Gilhuis HJ, Koster JG et al. Differential patterns of insulin-like growth factor-I and -II mRNA expression in medulloblastoma. Neuropathol Appl Neurobiol 2004; 30: 503-512.
20. Han VK, Bassett N, Walton J, Challis JR. The expression of insulin-like growth factor (IGF) and IGF-binding protein (IGFBP) genes in the human placenta and membranes: Evidence for IGF-IGFBP interactions at the feto-maternal interface. J Clin Endocrinol Metab 1996; 81: 2680-2693.
21. Van Glabbeke M, Verweij J, Casali PG et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005; 23: 5795-5804.
22. Hoekman K, Van Doorn J, Gloudemans T et al. Hypoglycaemia associated with the production of insulin-like growth factor II and insulin-like growth factor binding protein 6 by a haemangiopericytoma. Clin Endocrinol (Oxf) 1999; 51: 247-253.
23. Singh R, Grey A, Miller M et al. Non-hyperinsulinemic hypoglycemia in a patient with a gastrointestinal stromal tumor. Eur J Intern Med 2006; 17: 127-129.
24. Breccia M, Muscaritoli M, Aversa Z et al. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol 2004; 22: 4653-4655.
25. Billemont B, Medioni J, Taillade L et al. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 2008; 99: 1380-1382.
26. Clemmons DR. Modifying IGF1 activity: An approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007; 6: 821-833.
27. Trent JC, Ramdas L, Dupart J et al. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. Cancer 2006; 107: 1898-1908.
28. Braconi C, Bracci R, Bearzi I et al. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol 2008; 19: 1293-1298.
29. Baron-Hay S, Boyle F, Ferrier A, Scott C. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res 2004; 10: 1796-1806.
30. Renehan AG, Jones J, Potten CS et al. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 2000; 83: 1344-1350.
31. Ho PJ, Baxter RC. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxf) 1997; 46: 333-342.
32. Vorwerk P, Mohnike K, Wex H et al. Insulin-like growth factor binding protein-2 at diagnosis of childhood acute lymphoblastic leukemia and the prediction of relapse risk. J Clin Endocrinol Metab 2005; 90: 3022-3027.
33. Ranke MB, Maier KP, Schweizer R et al. Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma. Horm Res 2003; 60: 174-180.
34. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: Regulation and functions. Endocr Rev 1997; 18: 801-831.
35. Souba WW. Nutritional support. N Engl J Med 1997; 336: 41-48.